Compare · ELV vs GRAL
ELV vs GRAL
Side-by-side comparison of Elevance Health Inc. (ELV) and GRAIL Inc. (GRAL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and GRAL operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.24B, about 35.1x GRAL ($2.57B).
- Over the past year, ELV is up 7.4% and GRAL is up 53.9% - GRAL leads by 46.5 points.
- GRAL has been more active in the news (11 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 12 for GRAL).
PerformanceELV+7.41%GRAL+53.95%
2025-06-09+0.00%2026-06-08
- Company
- Elevance Health Inc.
- GRAIL Inc.
- Price
- $418.43+0.66%
- $61.74+2.96%
- Market cap
- $90.24B
- $2.57B
- 1M return
- +12.25%
- -2.00%
- 1Y return
- +7.41%
- +53.95%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 11
- Recent ratings
- 23
- 12
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest GRAL
- Chief Growth Officer Partridge Andrew John sold $91,070 worth of shares (1,491 units at $61.08), decreasing direct ownership by 0.90% to 163,738 units (SEC Form 4) (withholding obligation)
- Goldman initiated coverage on GRAIL with a new price target
- Chief Executive Officer Ofman Joshua J. was granted 31,055 shares, increasing direct ownership by 8% to 402,271 units (SEC Form 4)
- New insider Partridge Andrew John claimed ownership of 165,229 shares (SEC Form 3)
- Wolfe Research resumed coverage on GRAIL
- GRAIL Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
- GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
- GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference